No insider purchase over the last 90 days. The latest was filed 27 Jun 2025.
Every trade that managers of Zeo ScientifiX, Inc. disclose to SEC (Form 4) is tracked on this page. Between 18 October 2025 and 18 October 2026, 3 insiders published 3 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 3 filings, this issuer sits below that mark. Looking back to 2021, when coverage begins, insiders filed 27 purchases and 50 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 October 2025), the company reported revenue of 5.2 m USD and net income of -5.5 m USD.
There has been no open-market purchase by an insider of Zeo ScientifiX, Inc. for at least a year. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended October 2025 · cache
25 of 90 declarations
Zeo ScientifiX, Inc. is a company listed on the XNAS market, specializing in the development of innovative scientific solutions. It focuses on research and development in the field of advanced technologies.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Oct 2025 | 5.2 m USD | -5.5 m USD | -0.86 USD | 10-K |
| Oct 2024 | 4.6 m USD | -4.7 m USD | -0.74 USD | 10-K |
| Oct 2023 | 4.6 m USD | -7.0 m USD | -0.99 USD | 10-K |
| Oct 2022 | 6.5 m USD | -8.9 m USD | -1.56 USD | 10-K |
| Oct 2021 | 5.6 m USD | -12.8 m USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.